Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis

WWARN Parasite Clearance Study Group*

Abstract

Background: Artemisinin resistance in *Plasmodium falciparum* manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up.

Methods: Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC$_{1/2}$) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC$_{1/2}$ and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive.

Results: PC$_{1/2}$ was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluated during 28–63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC$_{1/2}$ following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC$_{1/2}$ > 5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC$_{1/2}$ by 8.1 % (95 % CI 3.2–12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC$_{1/2}$ was longer in children and in patients with fever or anaemia at enrolment. Long PC$_{1/2}$ (HR = 2.91, 95 % CI 1.95–4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44–3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC$_{1/2}$ since 2007.

Conclusions: Several factors affect PC$_{1/2}$. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC$_{1/2}$ data. Studies with frequent parasite count measurements to characterize PC$_{1/2}$ should be encouraged. In western Cambodia, where PC$_{1/2}$ values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.

Keywords: Malaria, Parasite clearance, Artemisinin resistance, Drug resistance, *Plasmodium falciparum*
Background
Parasite clearance is a robust measure of the efficacy of anti-malarial drugs, which has been used particularly to measure the pharmacodynamic effects of artemisinin derivatives [1]. Initial studies conducted in patients with severe malaria employed frequent parasite counting to characterize clearance profiles, and these demonstrated that artemisinin derivatives cleared parasitaemia more rapidly than quinine [2]. More recently, frequent parasite counting has been used to characterize artemisinin susceptibility in vivo [3], and to validate molecular markers [4, 5] and in vitro assays for detection of artemisinin resistance [6]. Parasite clearance following artemisinin treatment is influenced by a number of factors other than parasite susceptibility, including host immunity, initial parasite biomass and partner drug efficacy. It is therefore essential to control for such potential confounding factors in order to identify temporal changes in parasite clearance resulting from reduced anti-malarial drug susceptibility.

The WorldWide Antimalarial Resistance Network (WWARN) Parasite Clearance Estimator (PCE) [7] was developed to automate and standardize analysis of frequent parasite count data. This tool is freely available online [8] and provides an automated report for each patient. The derived measure, parasite clearance half-life (PC1/2), generated by the PCE reflects the extent to which ring-stage parasites are killed and removed from the circulation, and is currently considered the most reliable measure of parasitological responses to treatment with artemisinin or its derivatives [5, 9–16]. This standardized approach to PC1/2 measurement allows comparison in space and time of artemisinin resistance, which manifests as a slow parasite clearance rate in patients. Within the WWARN framework, investigators who obtained frequent parasite count data have joined several study groups [17] to evaluate this metric. This pooled analysis presents reference parasite clearance estimates stratified by geographic location, treatment and study population, and explores the relationship between parasite clearance measures and the risk of recrudescence infection (treatment failure). The effects of different sampling strategies on clearance estimates have been published separately [18].

Methods

Data acquisition
Any study involving patients with uncomplicated falciparum malaria, treated with either artemisinin combination therapy (ACT) or oral artesunate monotherapy, in which peripheral parasitaemia was measured at least twice daily in the first 3 days after starting treatment, was eligible for inclusion in this pooled analysis. In addition, the minimum data required were enrolment date, patient age, drug treatment, study location and characteristics, and details of the parasite counting method. Studies with frequent parasite counts were identified using literature reviews and existing collaborations within WWARN. Principal investigators were subsequently approached to participate in this study group [19]. The datasets uploaded to the WWARN repository were standardized using the WWARN Data Management and Statistical Analysis Plans for clinical data [20] and pooled into a single database of quality-assured individual patient data.

Parasite inclusion criteria, counting methods and blood sampling schedules were different among studies; for a detailed description see Additional file 1: Table S1.

Statistical analysis

Definitions
As a measure of transmission intensity, malaria endemicity estimates were obtained for study sites and year from the Malaria Atlas Project [21]. Anaemia was defined according to WHO guidelines [22], (i.e., haemoglobin concentration cut-offs for moderate anaemia were 10 g/dL in children <5 years of age and 11 g/dL in older patients, and for severe anaemia were 7 and 8 g/dL, respectively). For studies where haematocrit only was measured, the following relationship was used to estimate haemoglobin: haematocrit (%) = 5.62 + 2.60 \times \text{haemoglobin} (g/dL) [23]. Nutritional status of children aged <5 years was assessed by the weight-for-age indicator using the igrowup package developed by the WHO [24].

Analysis of parasite counts

PC1/2 was estimated only for patients with sufficient parasite counts defined as sampling at least 12-h in the first 48 h (a maximum of a 16-h gap between any two measurements, as a 2-h window on each side was allowed) and at least 24-h sampling (maximum 28-h gap) after 48 h until parasite clearance [18]. The following deviations from this rule were accepted as they were deemed not to have substantial effects on the PC1/2 estimate [18]: sampling was not performed until parasite clearance but the last recorded parasitaemia was <100 or <1000 parasites/µL with at least five positive parasite counts available; a longer gap was observed between a set of measurements but there were at least two positive parasite counts directly after the gap, or a zero count was recorded after the gap and the last recorded parasitaemia before the gap was either <100 or <1000/µL and at least five positive parasite count measurements were available before the gap.

PC1/2 was calculated by the PCE [7] for each patient (variable called slope_half_life in the output files), based on the linear segment of the decline in the log-transformed parasitaemia-time profile. A lag-phase (an initial, flat part of the parasitaemia-time profile which precedes the log-linear decline) and a tail (a levelling
out in the parasitaemia-time profile which follows the log-linear decline, if present, are identified by the PCE automatically.

Reliability of \( PC_{1/2} \) estimates was assessed by (a) the standard deviation of residuals from the final linear model used to estimate \( PC_{1/2} \); (b) the duration of the lag phase (as a long lag phase is very unlikely if an artemisinin derivative is given and absorption is adequate); (c) the number of positive parasite counts used in the estimation; (d) pseudo-R\(^2\) statistics; and, (e) the width of the 95 % confidence interval around the \( PC_{1/2} \).

Pseudo-R\(^2\) is a measure of goodness of fit of the final model and is provided by the PCE tool. Low values of pseudo-R\(^2\) indicate that the predicted values from the polynomial model are far from the measured parasitaemias. Pseudo-R\(^2\) is calculated from the fitted values of the final linear model used to estimate the \( PC_{1/2} \) (after exclusion of the lag phase and tail) and the observed log-parasitaemias, excluding zero counts.

### Parasite clearance and clinical covariates

Factors affecting \( PC_{1/2} \) were investigated in the random effects regression model (to account for study site heterogeneity) with \( PC_{1/2} \) being modelled after log transformation. Separate analyses were performed in artemisinin-resistant and artemisinin-sensitive areas. The resistant areas were defined as locations in which delayed parasite clearance had been reported previously [3, 9–11, 13, 17, 24] at 14 locations randomized 1242 patients to either 2 or 4 mg/kg daily doses of AS, alone or in combination with an ACT given at 72 h.

In studies which randomized treatment arms to 2 and 4 mg/kg/day artesunate doses, meta-analysis of the differences in mean log-transformed \( PC_{1/2} \) between treatment arms was performed using a fixed effects model using the inverse variance method. Heterogeneity was evaluated by \( I^2 \) [29].

### Analysis of treatment outcome

The risk of recrudescence was assessed by survival analysis using WHO definitions of therapeutic efficacy outcome [30]. Patients with no PCR results were excluded from the treatment outcome analysis. Cox regression model with random effects in the form of frailty parameters were used to adjust for study site effects [31]. The proportional hazard assumption was tested based on Schoenfeld residuals [32]. \( PC_{1/2} \), presence of a lag phase, duration of lag phase and presence of a tail were evaluated as possible predictors of outcome, together with all other baseline clinical and treatment characteristics.

Covariates for the final regression models (for treatment outcome and \( PC_{1/2} \)) were selected on the basis of the likelihood ratio test and examination of residuals. Relationship between the independent variable and continuous covariates such as age and parasitaemia was examined using fractional polynomials. All statistical analyses were performed using Stata 13.0.

### Results

#### Data summary

Data from 9318 patients enrolled from 1996 to 2013 in 24 studies [3, 9–15, 26, 33–43] (Additional file 2: Table S2; Fig. 1) conducted at 61 study sites in 46 distinct locations (Fig. 2) in 18 countries (Bangladesh, Benin, Burkina Faso, Cambodia, Democratic Republic of Congo, Gabon, Ghana, India, Kenya, Laos, Mali, Mozambique, Myanmar, Nigeria, Tanzania, Thailand, Uganda, Vietnam), were available for analysis.

Among hyperparasitaemic patients (Study ID 1), 882 of 3393 (26 %) patients were excluded from analysis because of one or more of the following: severe malaria (n = 108), slow parasite clearance and administration of rescue treatment with intravenous or intramuscular artesunate (n = 642), blood transfusion before clearance of parasites (n = 215), or incomplete treatment information (n = 19).

Table 1 shows the demographic and clinical parameters of patients with uncomplicated *Plasmodium falciparum* malaria who were included in this analysis.

Patients were treated with (a) artesunate (AS) alone (n = 842); (b) AS alone in the first 3 days or longer followed by a standard ACT: artemether-lumefantrine (AL); artesunate-amodiaquine (ASAQ); artesunate-mefloquine (ASMQ); or dihydroartemisinin-piperazine (DP) (n = 2751); (c) AL (n = 2217); (d) DP (n = 55); (e) ASMQ, with the first dose of MQ administered at a median (range) of 46 (0–71) hours (n = 1343); or (f) artesunate-chlorproguanil-dapsone (n = 914). There were also 341 hyperparasitaemic patients studied in Thailand (Study ID 1) who received AS together with either doxycycline or clindamycin.

The target daily dose of AS varied between 2 (n = 862, 24 %), 4 (n = 2,544, 71 %), 6 (n = 119, 3 %), and 8 (n = 66, 2 %) mg/kg, with patients in Cambodia receiving the higher doses of 6 or 8 mg/kg in one study. In two studies the initial dose of AS was higher than on subsequent days: in hyperparasitaemic patients in Thailand (Study ID 1: 4 mg/kg followed by 2 mg/kg, n = 2509) and in patients in Mali (Study ID 14: 6 or 4 mg/kg followed by 2 mg/kg, n = 100). Seven studies (Study IDs: 2, 6, 10, 11, 13, 17, 24) at 14 locations randomized 1242 patients to either 2 mg/kg or 4 mg/kg daily doses of AS, alone or in combination with an ACT given at 72 h.

### Estimates of parasite clearance

Among 8536 patients, 6975 (82 %) had sufficient parasite counts taken for PCE estimation of \( PC_{1/2} \). The majority
Fig. 1 Study profile

Fig. 2 Map of study sites included in the parasite clearance data analysis
of the excluded patients came from three studies with variable sampling schemes (59 %, Study IDs 4, 20, 21) and from the study with hyperparasitaemic patients (36 %, Study ID 1), which for 10 years routinely recorded parasitaemia every 6 h until clearance.

Only two positive parasite counts were used to estimate PC1/2 in 878 patients, either because only two positive measurements were available (n = 844) or measurements were excluded as being part of the lag or tail phases (n = 34). For these profiles with only two positive parasite counts available, the PCE replaces the first zero count with median (range) duration of 6 (1.5–60) h. For 21 % of profiles, a non-zero lag phase was estimated using one of the twice-daily schemes. For 21 % (1489/6975) of profiles, a non-zero lag phase was estimated using one of the twice-daily schemes. For 21 % (1489/6975) of profiles (175/226) had parasite counts >3 h, indicating that parasite clearance in these patients was rapid and thus provided no evidence for artemisinin resistance. Of the remaining patients, 73 % (165/226) with an estimated PC1/2 >3 h had an initial parasitaemia <10,000 parasites/µL and 77 % (618/844) had estimated values <2 h, indicating that parasite clearance in these patients was rapid and thus provided no evidence for artemisinin resistance. Of the remaining patients, 73 % (165/226) with an estimated PC1/2 >3 h had an initial parasitaemia <10,000 parasites/µL and 77 % (175/226) had parasite counts measured using one of the twice-daily schemes. For 21 % (1489/6975) of profiles, a non-zero lag phase was estimated with median (range) duration of 6 (1.5–60) h, with 6 % (90/1489) having a lag phase duration >12 h.

The median (range) goodness of fit statistic, pseudo-R², was 0.938 (−198 to 0.999), with 89 % (6197/6975) of profiles having a pseudo-R² >0.8. Only 0.9 % (65/6975) of profiles had a negative pseudo-R², indicating that the model was not a good representation of the data.

The 95 % confidence interval (CI) for the estimated PC1/2 was wide for 11 % (740/6975) of profiles; the 95 % CI either included negative values or the upper limit was greater than twice the PC1/2 estimate. Of these, 70 % (519/740) were for patients with only two positive parasite counts available.

For the distribution of PC1/2 by location, treatment and study year see Additional file 3. See Additional file 4: Table S3 for summaries of PC1/2 and other parasitological measures by location and treatment and 5: Table S4 for proportion of profiles with PC1/2 longer than 3, 4, 5 and 6 h.

Areas with slow parasite clearance

Delayed parasite clearance was observed at sites in Cambodia, Thailand, Myanmar, and Vietnam. For all treatments and locations, the longest PC1/2 were observed in three western Cambodian sites: Pailin, Tasanh and Pursat where data from 2007 to 2012 were available; study median PC1/2 ranged from 5.6 to 6.7 h, and the proportion of PC1/2 >5 h ranged from 61 to 80 %. Importantly, no significant trend of increasing PC1/2 was observed at these sites over that time interval. At the two other Cambodian sites, Ratanakiri and Preah Vihear, parasite clearance was significantly faster (p < 0.001; median PC1/2 of 3.0 and 3.8 h, and proportion of PC1/2 >5 h of 4 and 22 %, respectively) and also different between these two sites (p = 0.011).

In contrast, a disproportionate increase in PC1/2 was observed in western Thailand after 2003 (p < 0.001, fractional polynomials), with an average increase in PC1/2 of 7.1 % (95 % CI 5.7–8.6) per year after 2005. The PC1/2 values were similar in hyperparasitaemic and uncomplicated falciparum malaria patients from 2008 to 2011 (Additional file 3: Figure S2). Overall, the proportion of PC1/2 <3 h decreased from 67 % (n = 169) in 2003 to 11 % (n = 75) in 2012, and the proportion of PC1/2 >5 h increased from 6 to 55 % during this time period (Additional file 4: Table S4).

Areas with rapid parasite clearance

Among studies in areas with artemisinin-sensitive parasitaemia (n = 3208), patients who received AS 2 mg/kg (with or without partner drugs) or the standard six-dose AL regimen had longer PC1/2 values compared to patients who received AS 4 mg/kg (with or without partner drugs) by 7.3 % (95 % CI 1.9–12.9, p = 0.007) and 7.4 % (95 % CI 3.8–11.2, p < 0.001), respectively (Fig. 3). These comparisons are adjusted for study site and study design characteristics which affect PC1/2 estimates: (a) patients with twice-daily sampling (Study IDs 4, 13, 20, 21) had 16.2 % (95 % CI 7.6–25.6) longer PC1/2 compared to those with more frequent schedules (p < 0.001); (b) patients with insufficient number of data points to estimate lag phases had 31 % (95 % CI 26–37) longer PC1/2 than those with sufficient data (p < 0.001). Since patients with very low initial parasitaemias and short PC1/2 are excluded from

| Parameter               | Median (range) [n or n/N] |
|-------------------------|---------------------------|
| Age (years)             | 10 (0.1–70) [6970]        |
| Parasitaemia (/µL)      | 70,336 (1000–2,285,920) [6966] |
| Temperature (°C)        | 38.0 (34.1–41.5) [3266]   |
| Haemoglobin (g/dL)      | 124 (21.1–19.9) [1812]    |
| Haematocrit (%)         | 35.0 (11.3–50) [3251]     |
| Anaemiaa                |                           |
| None                    | 59 [2359/3966]            |
| Moderate                | 36 [1422/3966]            |
| Severe                  | 5 [185/3966]              |
| Feverab                 | 66 [2164/3266]            |
| Gametocytaemia          | 32 [1610/5045]            |
| Female                  | 35 [2417/6876]            |

a Defined according to WHO guidelines [23]. For studies where only haematocrit was measured, the following relationship was used to estimate haemoglobin concentration: Haematocrit = 5.62 + 2.60 × Haemoglobin [24]

b Defined as axillary temperature >37.5 °C

Table 1 Baseline characteristics of patients included in the analysis
the analysis because of insufficient data, this creates a negative association between the initial parasitaemia and PC$_{1/2}$ (Fig. 4). Mean PC$_{1/2}$ was estimated to decrease by 16% (95% CI 15–18) per tenfold increase in parasitaemia.

In artemisinin-sensitive areas, profiles with a lag phase had 6.4% (95% CI 3.6–9.1) shorter PC$_{1/2}$ compared to profiles without a lag phase (p < 0.001, adjusted for all the above factors). No association was observed between the duration of the lag phase and PC$_{1/2}$ among 687 patients with a non-zero lag phase (p = 0.220, adjusted for the above factors).

**Initial parasitaemia**

Studies differed in their admission parasitaemia inclusion criteria. It was assumed that the log-transformed initial parasitaemias followed a truncated normal distribution with lower and upper truncation consistent with the inclusion criteria. In all but five studies, there was no evidence against this assumption of truncated normality (p values ranged from 0.17 to 0.98); the exceptions were four multi-centre and/or multi-country studies (Study IDs 4, 21, 22, 23) and a study with two distinct age groups (Study ID 20; young children weighing 12–20 kg and older children weighing 20–40 kg). For these five studies, there was clear evidence of a multimodal distribution of initial parasitaemias.

**Parasite clearance and clinical covariates**

**Areas with rapid parasite clearance**

In artemisinin-sensitive areas (all countries in Africa, Laos, Bangladesh, Thailand before year 2000, Ratanakiri in Cambodia; n = 3208), after adjusting for study design factors, patient age and treatment were associated independently with PC$_{1/2}$. Adjusting for age changed the treatment effect very little. Patients who received 2 mg/kg AS or AL had 7.2% (95% CI 1.8–12.8) and 7.3% (3.7–11.0) longer PC$_{1/2}$, respectively, compared to patients who received 4 mg/kg AS (p ≤ 0.008). Young children cleared parasites more slowly than older patients: PC$_{1/2}$ was 11.3% (95% CI 2.6–20.8, p = 0.010) longer in infants aged <1 year and 9.4% (95% CI 3.5–15.7, p = 0.002) longer in children aged 1–4 years compared to older patients (Fig. 5a, b). There was no significant difference in PC$_{1/2}$ between children aged 5–14 years and adults (p = 0.129). The relationship between patient age and PC$_{1/2}$ was examined further in the multivariate model (Fig. 5c). After adjusting for age and treatment, higher parasitaemia remained associated with lower estimates of PC$_{1/2}$ (by a 17% (95% CI 15–18) per tenfold increase in parasitaemia). Other factors, examined on a subset of patients with available data, were independently associated with longer PC$_{1/2}$: fever (7.0%, 95% CI 3.2–10.8, p < 0.001, n = 1636); severe anaemia (13.5%, 95% CI 6.4–21.1, p < 0.001, n = 2043) and moderate anaemia defined as haemoglobin level from 7 to 9 g/dL (4.3%, 95% CI 1.0–7.7, p = 0.010, n = 2043). No associations between PC$_{1/2}$ and gametocyte carriage, transmission intensity or nutritional status of children were observed.

A lag phase was detected more frequently in patients receiving AL (OR = 2.14, 95% CI 1.29–3.59 compared to other treatments, p = 0.004), high initial parasitaemia (OR = 1.77, 95% CI 1.28–2.45 per tenfold increase, p = 0.001) or fever (OR = 1.63, 95% CI 1.21–2.21 compared to patients presenting without fever, p = 0.001). Among 1297 patients treated with AL [median (range) daily artemether dose 2 (0.9–4) mg/kg], no significant association was found between PC$_{1/2}$ and artemether dose. In contrast, none of the patient covariates or treatments were associated with a risk of PC$_{1/2}$ being >5 h.
Areas with slow parasite clearance

In areas with previously documented slow parasite clearance rates, no significant association between PC 1/2 and patient age was observed. After adjusting for study design factors, admission gametocytaemia was associated with an 11.1 % (95 % CI 5.5–16.9, p < 0.001, n = 3574) increase in PC 1/2, and temperature >37.5 °C was associated with a 7.3 % (95 % CI 1.3–13.8, p = 0.017, n = 1491) increase in PC 1/2. The relationship between PC 1/2 and initial parasitaemia was the opposite of that in the artemisinin-sensitive population: a tenfold increase in parasitaemia was associated with a 5.2 % (95 % CI 0.7–9.9, p = 0.024, n = 3574) increase in PC 1/2 when adjusted for study site.

Artemisinin dose and PC 1/2

Six studies at 15 locations had randomized AS treatment arms of 2 and 4 mg/kg. The higher dose was associated with an 8.1 % (95 % CI 3.2–12.6, p = 0.001) decrease in PC 1/2 in sites with geometric mean PC 1/2 <4 h (in AS 2 mg/kg dose arm), whereas there was no significant (p = 0.455) difference in PC 1/2 in the remaining sites with geometric mean PC 1/2 ≥4 h. Overall change was estimated as −5.5 % (95 % CI −9.7 to −1.2, p = 0.013) (test for heterogeneity between groups, p = 0.031) (Fig. 6).

Treatment outcome

Among 3328 patients with defined outcome, 93 (2.8 %) had PCR-confirmed recrudescences by day 63. After adjusting for study design factors in a multivariate model, longer PC 1/2 was associated with an increased risk of recrudescence: HR = 2.91, 95 % CI 1.92–4.31, for a doubling of PC 1/2, p < 0.001). Patients with high initial parasitaemia also had a higher risk of recrudescence: HR = 2.23, 95 % CI 1.44–3.46, for a tenfold increase in parasitaemia, p < 0.001. No significant interaction between PC 1/2 and initial parasitaemia was detected. After adjusting for the initial parasitaemia, PC 1/2 and parasite sensitivity status, the recrudescence rates varied...
between regimens with different partner drugs or time of their administration. Recrudescence rates were significantly higher in patients receiving artesunate-chlorproguanil-dapsone than any other ACT (HR = 3.62, 95 % CI 1.74–7.52, p = 0.001) Recrudescence rates were significantly lower in patients receiving AS for 3 days followed by a standard ACT at 72 h (HR = 0.28, 95 % CI 0.11–0.74, p = 0.010) than in all other patients. Other baseline covariates, as well as the presence or duration of lag and tail phases in the parasite clearance curve, were not associated with treatment outcome.

Discussion
The rate at which asexual *P. falciparum* parasites are cleared from the blood following treatment is the best measure of the anti-malarial effect of artemisinin and its derivatives. This is assessed from the linear component of the log-linear decline in parasite densities and is expressed conveniently as PC1/2 [1]. Resistance to artemisinins results in prolongation of the PC1/2. This pooled analysis combines the largest set of data, collected in 24 studies over 18 years, from nearly 7000 patients with uncomplicated falciparum malaria in whom frequent measurements of parasitaemia were made. The reference PC1/2 estimates provided for 46 locations across Africa and Asia are essential comparators for the early recognition of emerging resistance, and so will be updated continuously as others join the WWARN [44] collaborative effort and provide relevant data sets. An important output of this analysis is that there was no evidence for worsening of artemisinin resistance in western Cambodia. There is substantial concern that failure to eliminate falciparum malaria in this area, the ‘cradle of antimalarial drug resistance’, will lead to higher levels of artemisinin resistance, rendering ACTs progressively less effective. While further worsening of the degree of artemisinin resistance fortunately has not happened, at least until 2012, continued monitoring is vital.

This large dataset allowed estimation of the additional contributions of patient characteristics and study design to parasite clearance estimates, information that is crucial in interpreting and monitoring changes in these estimates, and attributing them to true artemisinin resistance rather than the effects of partner drugs, study design or patient characteristics. The recent discovery [4] and validation [15] of the molecular marker *kelch13* in the Greater Mekong area and the development of suitable in vitro sensitivity tests [6, 45] provide important information. Data from in vitro ring-stage survival assays do reflect artemisinin resistance in vivo, but their use is likely to be limited to few resourced laboratories and thus unlikely to provide comprehensive surveillance information across endemic countries. Mutations in *kelch13*
Estimation of PC\textsubscript{1/2} requires sufficient quality-assured serial parasite blood counts for analysis. In this very large series, the most common problem encountered (13%) was that only two positive counts were available because of rapid parasite clearance and low initial parasitaemias. Other problems encountered (10%) were a very long lag phase, large variations in parasite counts resulting in poor fits or large confidence intervals around the estimate. These were most likely a consequence of inaccurate microscopy counts. The initial parasitaemia and frequency of sampling had the greatest effects on the PC\textsubscript{1/2} estimates, which accords with results of a previously reported simulation study [18]. Ideally, only patients with initial parasitaemia >10,000 parasites/µL should be included in PC\textsubscript{1/2} assessments. In patients with only two positive parasite counts, estimated PC\textsubscript{1/2} should be interpreted with caution as it is likely to be overestimated. This is because the lag phase cannot be evaluated and the first recorded zero parasitaemia is treated as a parasite density at the detection limit (so the worst case scenario is assumed). Profiles for which the lag or tail phases were identified, and after their exclusion only two data points were left for the PC\textsubscript{1/2} estimation, should be excluded from analysis as they likely represent limitations in microscopy-based parasite counting.

A lag phase was detected more frequently in patients presenting with fever, possibly because of the association of fever with synchronous schizont rupture. The more frequent lag phase with AL treatment may result from the initial lower dose and slower absorption and conversion to DHA of oral artemether compared to oral artesunate [46]. Patients with profiles beginning with a lag phase may have had more rapid clearance in the log-linear part of the parasitaemia-time curve (lower PC\textsubscript{1/2}); however, the difference was rather small (6.4%, 95% CI 3.6–9.1). This is an artefact of the way the model is fitted—as the lag phase is defined only if the initial clearance is slower and the ratio of the clearance rates between this initial period and the rest of the parasitaemia profile reaches a pre-specified cut-off. Some of the observed differences in slopes are caused by random variation of the microscopy measurement. Excluding this randomly occurring slower (but not faster) part of the profile will result in the overestimation of PC\textsubscript{1/2} in profiles with a detected lag phase. This phenomenon was observed in 3–10% of simulated parasite profiles (using previously described methodology [18]), from distributions of PC\textsubscript{1/2} with mean of two to 6 h and standard deviation (log scale) from 0.05 to 0.3.

The relationship between PC\textsubscript{1/2} and parasitaemia was different between the sensitive and resistant parasite populations. In sensitive areas, high parasitaemia was associated with shorter PC\textsubscript{1/2} largely because patients with low initial parasitaemias and rapid clearance are not included...
Additional files

Additional file 1: Table S1. Methods used for counting parasites. Summary of the methodologies used in individual studies to measure parasitemia.

Additional file 2: Table S2. Description of 24 studies included in the analysis. Description of studies included in the analysis with respect to location and year, treatment administered and study population.

Additional file 3: Figures S1-S5. Distribution of sampling. Box plots of PC1/2 by study location, treatment and year. Box plots of PC1/2 by study location, treatment and study year.

Additional file 4: Table S3. Summary of parasitological measures I: PC1, PC50 and PC90 summarized by study location, year and treatment.

Additional file 5: Table S4. Summary of parasitological measures II: Proportion of profiles with PC1/2 above cut-off of 3, 4, 5 and 6 h presented by study location, year and treatment.

Authors' contributions

KS, PJG and NJW designed the study. SA, EAA, QB, DB, AB, SB, UDA, NPD, MD, AD, AM, MM, OA, PN, HH, FN, BO, MAO, SOA, APP, ZP, SP, MR, IS, YS, SS, SAW, NW, and PAW performed the original studies. KS, JAF, CM, and PD analysed the pooled individual patient data. KS, JAF, NJW, EAA, and PJG wrote the first draft of the manuscript; all other authors critically reviewed the draft. All authors read and approved the final manuscript.

Acknowledgements

We thank the patients and staff who participated in the clinical trials at all sites. WWARN is funded by a Bill and Melinda Gates Foundation grant. The funder did not participate in developing the protocol or writing the paper. This study was supported in part by the Intramural Research Program of the NIAID, NIH. All clinical studies were approved by the respective ethics committees or institutional review boards of each collaborative entity and host country of conduct. All subjects provided informed consent before study participation, and parents or legal guardians provided informed consent on behalf of their children. Disclaimer: The opinions expressed are those of the authors and do not necessarily reflect those of the Australian Defence Organisation or any extant policy.

The members of the WorldWide Antimalarial Resistance Network (WWARN) Parasite Clearance Study Group are the authors of this paper: Salim Abdulla, Ifakara Health Institute, Dar es Salaam, Tanzania (salabdulla@ihi.or.tz); Elizabeth A Ashley, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK and Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (e.ashley@tropmedres.ac); Quique Bassat, Centro de Investigación en Salud de Manchí, Manchí, Mozambique and ISGlobal, Barcelona Center for International Health Research (CRESIB), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain (quique.bassat@cresib.org); Delia Bethell, Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand (delia.bethell@binternet.com); Anders Björkman, Malaria Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden (anders.bjorkman@ki.se); Steffen Borrmann, Kenya National Research Institute / Wellcome Trust Research Programme, Kilifi, Kenya and Magdeburg University School of Medicine, Germany (sborrmann@kilifi.kinetics-wellcome.org). Umberto D’Alessandro, Unit of Malariaology Tropical Institute of Medicine, Antwerp, Belgium and Medical Research Council Unit, Fajara, The Gambia (udalessandro@mrc.gm); Prabin Dahal, WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK (prabin.dahal@wwarn.org); Nicholas P Day, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK and Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (nckid@tropmedres.ac); Mahamadou Diakite, Malaria Research and Training Centre, University of Bamako, Bamako, Mali (m.madiakite@icermali.org); Abdoulaye A Djimde, Malaria Research and Training Centre, University of Bamako, Bamako, Mali (adjimde@icermali.org); Anjen M Dondorp, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK and Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (arend@tropmedres.ac); Socheat Duong, Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia (scheat@yahoo.com); Michael D Edstein, Australian Army Malaria Institute, Brisbane, Australia (michael.edstein@defence.gov.au); Rick M Fairhurst, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States (fairhurst@niaid.nih.gov); M. Albul Faiz, Malaria Research Group (MRG) & Dev Care Foundation, Dhaka, Bangladesh (drafafa@gmail.com); Catherine Felade, College of Medicine, University of Ibadan, Ibadan, Nigeria (billyfunke@yahoo.com); Jennifer A Flegg, School of Mathematical Sciences, Monash University, Melbourne, Australia (jennifer.flegg@monash.edu); Carole Fogg, University of Portsmouth, Portsmouth, UK (carole.fogg@port.ac.uk); Raquel Gonzalez, Centro de Investigação em Saúde de Manchí, Manchí, Mozambique and Centre for Recherche en Salut International de Bordeaux (CRESIB), Bordeaux, France (raquel.gonzalez@cercem.org); Brian Greenwood, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK (brian.greenwood@lshtm.ac.uk); Philippe J Guérin, WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (philippe.guerin@wwarn.org); Jean-Paul Guthmann, Epicentre, Paris, France (j.p.guthmann@invs.sante.fr); Kamal Hamed, Novartis Pharmaceuticals Corporation, East Hanover, USA (kamal.hamed@novartis.com); Tran Tinh Hien, Oxford University Clinical Research Unit (OUCRU), Wellcome Trust Major Overseas Programme (MOP), Vietnam and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (tien@ooucru.org); Ye Htut, Department of Medical Research, Lower Myanmar, Yangon, Myanmar (dy.ymhtut@gmail.com); Elizabeth Juma, Kenya Medical Research Institute, Nairobi, Kenya (jumaelizabeth@yahoo.com); Pharath Lim, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States and National Center for Parasitology, Entomology and...
Malaria Control, Phnom Penh, Cambodia (limp@niaid.nih.gov), Andreas Mårtensson. Malaria Research, Department of Microbiology, Cell and Tumour Biology, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden and Center for Clinical Research Sormland, Uppsala University, Uppsala, Sweden (andreas.martensson@ki.se), Mayfong Mayxay, Lao-Oxford-Mahosot Hospital-Welcombe Trust-Research Unit (LOMWU), Mahosot Hospital, Vientiane, Laos and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK; and Faculty of Postgraduate Studies, University of Health Sciences, Vientiane, Laos (mayfong@tropmedres.ac.au), Olungenga A Mokuolu. Department of Paediatrics and Child Health, University of Ile-Ife, Ile-Ife, Nigeria (aomokuolu@yahoo.com), Clarissa Moreira. WorldWide Anti-malarial Resistance Network (WWARN), Oxford, UK and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK; and Paul Newton. Lao-Oxford-Mahosot Hospital-Welcombe Trust-Research Unit (LOMWU), Mahosot Hospital, Vientiane, Laos and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, UK (paul@tropmedres.ac.uk), Harald Noedl. Institute of Specific Phytophaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria (harald.noedl@meduniwien.ac.at), Francois Nosten. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (francois@tropmedres.ac.uk), Bernhards R Ogotu. Kenya Medical Research Institute/United States Army Medical Research Unit, Kisumu, Kenya (bernhards.ogotu@usamru-k.org), Marie A Onyamboko. Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (akathsimarie@yahoo.fr), Seth Owusu-Agyei. Kintampo Health Research Centre, Kintampo, Ghana (seth.owusu-agyei@kintampo-hrc.org), Aung Pyae Phyo. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (aungpyaephyo@shoklo-unit.com), Zul Premji. Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (zulpromji6@gmail.com), Rich N Price. WorldWide Anti-malarial Resistance Network (WWARN), Oxford, UK, and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK and Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia (nc.price@wwarn.org), Sasithon Pukrittayakamee. Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (sak@tropmedres.ac.th), Michael Ramharter. Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University Vienna, Vienna, Austria and Institut für Tropenmedizin, University of Tuebingen, Germany and Centre de Recherches Médicales de Lambaréné, Gabon (michael.ramharter@meduniwien.ac.at), Issaka Sagara. Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-Stomatolog. University of Samakco, Bamako, Mali (issagara@mrctckb.org), Youn Y Se (deceased), Armed Forces Research Institute of Medical Sciences (AFRIMS), Phnom Penh, Cambodia, Seilla Sou. National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia (seilla.sou02@yahoo.com), Kasia Stepniewska. WorldWide Anti-malarial Resistance Network (WWARN), Oxford, UK and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (kasia.stepniewska@wwarn.org), Stephen A Ward. Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK (saward@liverpool.ac.uk), Nicholas J White. Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK and Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (n.jwhite@tropmedres.ac.uk), Peter A Winstanley. Warwick Medical School, University of Warwick, Coventry, UK (P.Winstanley@warwick.ac.uk).

Compliance with ethical guidelines

Competing interests

KH is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. UDA received travel money from Novartis. This declaration is made in the interest of full disclosure and not because the authors consider this to be a competing interest. All other authors declare that they have no competing interests.

Received: 23 March 2015 Accepted: 26 August 2015
Published online: 22 September 2015

References

1. White NJ. The parasite clearance curve. Malar J. 2011;10:278.
2. Tran TH, Day NP, Nguyen HP, Nguyen TH, Pham PL, Dinh XS, et al. A controlled trial of artether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335:76–83.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyoh AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:655–67.
4. Aney F, Witkowski B, Amarantunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
5. Takala-Harrison S, Clark TG, Jacob CG, Cummings MR, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artesunate treatment in Southeast Asia. Proc Natl Acad Sci USA. 2013;110:240–5.
6. Witkowski B, Amarantunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug-response studies. Lancet Infect Dis. 2013;13:1043–9.
7. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.
8. Parasite Clearance Estimator [http://www.wwarn.org/tools-resources/ toolkit/analysis/parasite-clearance-estimator-pce]. Accessed 8 Sept 2015.
9. Amarantunga C, Sreng S, Suon S, Pheps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.
10. Das D, Trippu R, Phyoh AP, Lwin KM, Tarning J, Lee SJ, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis. 2013;56:e48–58.
11. Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Birh Phuoc Province, Vietnam. Malar J. 2012;11:355.
12. Lopera-Mesa TM, Doumbia S, Chang S, Zeituni AE, Kone NT, et al. Plasmodium falciparum glucose-6-phosphate dehydrogenase deficiency and anemia in children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655–63.
13. Mayxay M, Khanthavong M, Chanthongthip O, ounmang M, Lee SJ, Stepniewska K, et al. No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos. Am J Trop Med Hyg. 2012;86:403–8.
14. Phyoh AP, Nkhora S, Stepnevskia K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
15. Ashley EA, Dhorda M, Fairhurst RM, Amarantunga C, Lim P, Suon S, et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med. 2014;371:1–23.
16. Kaew MP, Nyunt MH, Chit K, Aye MM, Aye KH, Lindegardh N, et al. Reduced susceptibility of Plasmodium falciparum to artemisinin in southern Myanmar. PLoS One. 2013;8:e57568. 17. WWARN Study Groups [http://www.wwarn.org/working-together/study- groups]. Accessed 8 Sept 2015.
18. Flegg JA, Guerin PJ, Nosten F, Ashley EA, Phyoh AP, Dondorp AM, et al. Optimal sampling designs for estimation of Plasmodium falciparum parasite clearance rates in patients treated with artemisinin derivatives. Malar J. 2013;12:411.
19. WWARN Parasite Clearance Study Group [http://www.wwarn.org/working-together/study-groups/parasite-clearance-study-group]. Accessed 8 Sept 2015.

Page 11 of 12
21. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map. Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
22. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. [http://who.int/vmnis/indicators/haemoglobin.pdf]. Accessed 8 Sept 2015.
23. Lee SJ, Stepnewksia K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J. 2008;7:149.
24. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Heal Organ; 2006. p. 312.
25. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
26. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PloS One. 2011;6:e19283.
27. World Malaria Report 2013. World Health Organization. 2013.
28. World Malaria Report 2013. World Health Organization. 2013.
29. Noedl H, Se Y, Sriwichai S, Schaecher K, Smith BL, Socheat D, et al. Artesinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–9.
30. Higgins JPT, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
31. WHO. Methods for surveillance of antimalarial drug efficacy. 2009. [http://whqlibdoc.who.int/publications/2009/9789241597531_eng.pdf]. Accessed 8 Sept 2015.
32. Glidden DV, Vittinghoff E. Modelling clustered survival data from multi-centre clinical trials. Stat Med. 2004;23:369–88.
33. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1986;73:239–41.
34. Abdulla S, Sagara I, Borrman S, D’Alessandro U, Gonzalez R, Hamel M, et al. Efficacy and safety of artesunate-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multi-centre trial. Lancet. 2008;372:1819–27.
35. Bouyou-Akotet MK, Ramharter M, Ngoungou EB, Mamfoumbi MM, Mihindou MP, Missinou MA, et al. Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Wien Klin Wochenschr. 2010;122:173–8.
36. Falade C, Makanga M, Premji Z, Ortmann C-E, Stockmeyer M, de Palacios PI. Efficacy and safety of artesunate-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005;99:459–67.
37. Fogg C, Twesige R, Batwala V, Piola P, Nabasumba C, Kurita J, et al. Assessment of three new parasite lactate dehydrogenase (pan-pLDH) tests for diagnosis of uncomplicated malaria. Trans R Soc Trop Med Hyg. 2008;102:25–31.
38. Hietala SF, Martensson A, Ngasala B, Dahlistrom S, Lindegardh N, Annerberg A, et al. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2010;54:4780–8.
39. Maiga AW, Fofana B, Sagara I, Dembele D, Ara D, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87:23–8.
40. Premji Z, Umeh OE, Owsusu-Agyei S, Esami F, Ezedinachi EU, Oguche S, et al. Chlorproguanil-dapsono-artesunate versus artesunate-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PloS One. 2009;4:e6682.
41. Thanh NX, Trung TN, Phong NC, Quang HN, Dai B, Shanks GD, et al. The efficacy and tolerability of artesinin-piperazine (Artesquin®) versus artesunate-amodiaquine (Coarsucam®) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J. 2012;11:127.
42. Vugt NV, Wilaaratana P, Gemperli B, Gathmann I, Piola P, Hoflecker V, Siedl A, et al. Current status of artesinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Banglades. PloS One. 2012;7:e52236.
43. World Wide Antimalarial Resistance Network. [http://www.wwarn.org/]. Accessed 8 Sept 2015.
44. Chotivanich K, Tripura R, Das D, Yi P, Day N, Pukrittayakamee S, et al. Laboratory detection of artesinin-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2014;58:5157–61.
45. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, Rasameeors J, et al. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol. 2001;52:655–61.
46. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukun F, et al. Early parasite clearance following artesinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:32.
47. Das D, Price RN, Bethell D, Guerin PJ, Stepniewska K. Early parasitological response following artesinin-containing regimens: a critical review of the literature. Malar J. 2013;12:125.
48. Borrman S, Sasi P, Mwai L, Bashreihel M, Abdallah A, Murithi S, et al. Declining responsiveness of Plasmodium falciparum infections to artesinin-based combination treatments on the Kenyan coast. PLoS One. 2011;6:e26005.
49. Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Green M, et al. Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum. Malar J. 2008;7:149.
50. Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Green M, et al. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission. Thorough peer review. Inclusion in PubMed, CAS, Scopus and Google Scholar. Immediate publication on acceptance. Convenient online submission.